Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer

Prof Frederik Marmé - Heidelberg University, Heidelberg, Germany
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer ( Prof Frederik Marmé - Heidelberg University, Heidelberg, Germany )
2 Jun 2024

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes

Prof Jean-Marc Classe - Nantes Université, Nantes, France
Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes ( Prof Jean-Marc Classe - Nantes Université, Nantes, France )
2 Jun 2024

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
2 Jun 2024

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi
Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )
2 Jun 2024

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA
Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )
2 Jun 2024

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Prof Don Dizon - Lifespan Cancer Institute, Providence, USA
Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas ( Prof Don Dizon - Lifespan Cancer Institute, Providence, USA )
2 Jun 2024

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA
Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )
2 Jun 2024

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China
Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy ( Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China )
1 Jun 2024

Monitoring ovarian function in oncology studies

Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA
Monitoring ovarian function in oncology studies ( Dr Elizabeth Trice Loggers - University of Washington, Seattle, USA )
1 Jun 2024

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain
Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )
1 Jun 2024

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC ( Dr Guillermo Villacampa  - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
21 May 2024

CAR-T, bispecifics or ADCs in late-stage RRMM

Dr Elena Zamagni - University of Bologna, Bologna, Italy
CAR-T, bispecifics or ADCs in late-stage RRMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
8 May 2024